Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.84 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.84 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8928118 | 0.92 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL8928088 | 0.90 | MTNR1A (0.92) | MTNR1AMTNR1B | |
| SCHEMBL31036087 | 0.89 | MTNR1A (0.90) | MTNR1AMTNR1B | |
| SCHEMBL24528927 | 0.89 | MTNR1A (0.67) | MTNR1AMTNR1B | |
| SCHEMBL29722609 | 0.89 | MTNR1A (0.67) | MTNR1AMTNR1B | |
| SCHEMBL11654998 | 0.88 | CA1 (0.77) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL330142 | 0.88 | ALDH1A1 (0.76) | MTNR1AMTNR1BCA1CA2 | |
| Hydrochloric Acid SCHEMBL11659562 | 0.87 | CA1 (0.76) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL17143946 | 0.86 | ALDH1A1 (0.74) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL4028224 | 0.86 | CA1 (0.70) | MTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| WO-2016169911-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-10-27 | — | — | WO | disclosed |
| US-20120252807-A1 | ARBOVIRUS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | MTNR1A 238/4885MTNR1B 412/4885CA1 2978/4885 |
| US-20120252807-A1 | ARBOVIRUS INHIBITORS AND USES THEREOF | ACE, ACE2, MME | MTNR1A 2193/4885MTNR1B 1545/4885CA1 4292/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MTNR1A 1704/4885MTNR1B 1599/4885CA1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.